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Induced pluripotent stem (iPS) cells are promising tools to investigate disease mechanism and develop
new drugs. Intraneuronal transport, which is fundamental for neuronal survival and function, is
vulnerable to various pharmacological and chemical agents and is disrupted in some neurodegenerative
disorders. We applied a quantiﬁcation method for axonal transport by counting CM-DiIelabeled particles
traveling along the neurite, which allowed us to monitor and quantitate, for the ﬁrst time, intraneuronal
transport in human neurons differentiated from iPS cells (iCell neurons). We evaluated the acute effects
of several anti-neoplastic agents that have been previously shown to affect intraneuronal transport.
Vincristine, paclitaxel and oxaliplatin decreased the number of moving particle along neurites. Cisplatin,
however, produced no effect on intraneuronal transport, which is in contrast to our previous report
indicating that it inhibits transport in chick dorsal root ganglion neurons. Our system may be a useful
method for assessing intraneuronal transport and neurotoxicity in human iPS neurons.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Intraneuronal transport is fundamental for neuronal survival,
morphogenesis, and homeostatic functions (1e4). Many proteins,
mRNAs, and organelles are selectively carried to their ﬁnal desti-
nations, either axons or dendrites, within neurons. This movement
along microtubules is powered by the molecular motors of the
kinesins and dynein super families. Recently, signal-dependent
regulation of intracellular transport has drawn attention (5). For
instance, retrograde axonal transport mediates the biological effect
of the axon guidance molecule semaphorin3A and regulates den-
dritic localization of AMPA-type glutamate receptors and dendritic
patterning (4). These ﬁndings illustrate the importance of intra-
cellular transport in regulating higher functions of the nervous
system. Disturbances in axonal transport and accumulations of
organelles and proteins in axons, dendrites, and/or cell bodies
contribute to the pathogenesis of many human neurodegenerative
diseases (6e10). In addition, disruption of intraneuronal transport
has been implicated in neuropathy induced by anti-neoplastic: þ81 45 785 3645.
(Y. Goshima).
rmacological Society.
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d/4.0/).agents (11, 12). Thus, a simple, accurate, and objective evaluating
system for intraneuronal transport is needed.
We previously developed a computer-assisted system for
quantifying axonal transport by counting moving organelles
labeledwith chloromethylbenzamide dialkycarbocyanine (CM-DiI),
a lipophilic dye, along the axons of chick dorsal root ganglion (DRG)
neurons (1). The aim of the current study was to establish a system
to monitor intraneuronal transport in human neurons differenti-
ated from induced pluripotent stem (iPS) cells by employing iCell
neurons, which are now commercially available (13e15). For this
purpose, we characterized the intracellular transport of iCell neu-
rons and evaluated how it was affected by anti-neoplastic agents
that are known to exert neurotoxicity by affecting axonal transport
(1, 11, 12). Our system may be a useful tool for assessing neuro-
toxicity based on transport in human iPS neurons.
2. Materials and methods
2.1. Materials
CM-DiI was purchased from Invitrogen (Eugene, OR, USA). Poly-
D-lysine hydrobromide, laminin, vincristine sulfate salt, 5-nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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and oxaliplatinwere from Sigma (St. Louis, MO, USA). Paclitaxel and
methotrexate were from Wako Pure Chemicals (Osaka, Japan).
2.2. Culture of human iPS neurons
iCell neurons were provided from Cellular Dynamics Interna-
tional (CDI, Madison, WI, USA). The human iPS cells used to
generate iCell Products were independently derived for research
use from a well-characterized, commercially available human
ﬁbroblast cell population originally isolated under the guidance of
the National Institute on Aging and the National Institutes of
Health. The cells were obtained under the informed consent prac-
tices in place at that time. iCell neurons were plated at concentra-
tions of 5.4  104 cells per dish on 35-mm cell culture glass-based
dishes (Iwaki, Tokyo, Japan) pre-coated with poly-D-lysine (50 mg/
ml) and then with laminin (3.3 mg/ml) in water. iCell neurons were
cultured in the iCell Neurons Maintenance Medium supplemented
with iCell NeuronsMedium Supplement (CDI). The culture medium
exchange was performed 24 h after plating and was repeated every
2e3 days until the start of the experiment. iCell neurons were ﬁxed
for immunostaining or loaded with CM-DiI at 5e16 days in vitro
(DIV) for monitoring intraneuronal transport.
2.3. Immunocytochemistry
Immunocytochemistry was done by a standard protocol under
permeabilization with 0.1% TritonX-100. The antibodies used for
the staining of cultured iCell neurons were as follows: anti-Tau1
mouse monoclonal antibody (MAB3420, 1:500 dilution, Millipore,
Billerica, MA, USA) and anti-MAP2 rabbit polyclonal antibody (PRB-
547C, 1:500 dilution, Covance, Princeton, NJ, USA). Immunostained
neurons were analyzed by laser-scanning microscope (LSM510)
with a water-immersed objective lens at  40 (C-Apochromat/
1.2 W corr) equipped with an Axioplan 2 imaging microscope (Carl
Zeiss, G€ottingen, Germany).
2.4. Live imaging and application of anti-neoplastic agents
iCell neurons stained with CM-DiI were observed by confocal
microscopy. To visualize the moving particles, neurons were ﬁrst
cultured for 30 min in the medium containing CM-DiI (1 mM),
washed three times in Leibovitz's L-15 medium (L-15 medium)
(Invitrogen, Auckland, NZ), and then incubated for 4 h in CM-DiI-
free culture medium to remove any excess dye loaded in the iCell
neurons. CM-DiI-labeled moving particles along the neurites were
observed by a laser-scanning microscope (LSM5 PASCAL) equipped
with an Axioplan 2 imaging microscope (Carl Zeiss) with a water-
immersed objective set at  40 (C-apochromat/1.2 W corr). The
images were typically 644.00 by 130.00 pixels, corresponding to an
image size of 75.00 by 15.10 mm with a pixel size of 0.116 mm
(~0.12 mm). The images were collected every 500.00 ms, at intervals
of 0.25 ms, for 2.00 min. For quantiﬁcation of the motility of the
particles, the 240 images captured during 2 min were analyzed by
computer-assisted software. To minimize data ﬂuctuation, we
estimated the total number of particles, deﬁned as the summation
of the data obtained at 74 points at 1.00-mm intervals along the
length of the neurite starting from the origin of the neurite (1).
Particles ranging in diameter size from 0.93 to 1.86 mm diameter
were extracted for the estimation in this system. This particle size is
consistent with that of vesicles containing GAP-43-GFP ranging
from 0.2 to 4.2 mm (16). Electron microscopic analysis of the
structure of the axoplasm by the method of quick-freezing and
deep-etching revealed that the size of mitochondria or lysosome is
within the range of 0.5e2 mm (17). Based on this vesicular size, it isunlikely that the vesicles consisted of several small independent
vesicles. This assay system requires imaging transport within
neurites that are longer than 70 mm. The velocity histogram of the
intraneuronal transport was obtained from the quantitative anal-
ysis using this software. To investigate the effects of anti-neoplastic
agents, iCell neurons were incubated for 24 h in the presence or
absence of the agents, and the intraneuronal transport of CM-
DiIelabeled particles was then monitored as described above.
2.5. Cytotoxicity of CM-DiI on chick DRG neurons
After 24-h incubation in the presence or absence of CM-DiI
(1 mM), cell viability was assessed by the 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay (18).
2.6. Statistical analysis
Two-tailed Student t-test was applied to the data as indicated in
the ﬁgure legends. Differences were considered to be signiﬁcant at
P < 0.05. All data in the text and ﬁgures are presented as
means ± SEM.
3. Results
3.1. Characterization of iCell neurons
iCell neurons generated through a proprietary forebrain differ-
entiation protocol represent a pure neuronal population, mainly of
forebrain identity, consisting of a mixed proportion of gluta-
matergic and GABAergic neurons (19). Functional studies showed
that these neurons express ionotropic glutamate receptors,
gamma-aminobutyric acid type A receptors, voltage-gated sodium
and calcium channels (14). To further characterize the neurons at
different stages of culture, immunocytochemistry was done at 5
and 19 DIV. Neurites stained equally with antibodies against MAP2
and Tau1, which are dendrite and axon marker proteins, respec-
tively (Fig. 1). The equal staining suggests that iCell neurons did not
acquire their axon-dendrite polarity during in vitro developmental
stages. Meanwhile, Nomarski images showed a subtle morpho-
logical difference of the neurons at these stages of culture: neurons
at 16 DIV generally had pyramidal-like cell bodies with neurites,
while those at 5 DIV had spindle-shaped cell bodies with long bi-
polar projections (Fig. 2A and B). Nevertheless, there were no dif-
ferences in the mean number of neurites per cell (3.20 ± 0.35 at 5
DIV, 3.50 ± 0.26 at 16 DIV) or in the length of neurites
(55.15 ± 6.38 mm at 5 DIV, 54.16 ± 5.33 mm at 16 DIV) (n ¼ 10)
(Fig. 2A and B).
3.2. Visualization of CM-DiI-labeled moving particles along the
neurites
After the destaining procedure, approximately one third of the
neurons per culture dish were still positive with CM-DiI. In these
neurons, CM-DiIelabeled particles that were moving were clearly
visualized along neurites under confocal microscopy (Fig. 2C and
D). There were no morphological differences between CM-
DiIepositive and CM-DiIenegative neurons at 5 and 16 DIV (Fig. 2A
and B). For example, the mean number of neurites per cell and the
length of neurites in CM-DiIepositive and CM-DiIenegative neu-
rons were 3.41 ± 0.33 and 55.19 ± 5.50 mm (n ¼ 12) and 3.41 ± 0.31
and 52.69 ± 4.79 mm (n ¼ 12), respectively.
We estimated that the number of CM-DiIelabeled particles
moving in both anterograde and retrograde directions was
12e13 particles/min, which was lower compared to the number of
moving particles detected by differential interference contrast
Fig. 1. Distribution of MAP2 and Tau1 proteins in the human iPS neurons (iCell neurons). iCell neurons cultured for 5 and 19 days in vitro (DIV) were ﬁxed and immunostained
with anti-MAP2 and anti-Tau1 antibodies. Scale bar ¼ 50 mm.
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Merge
D
Fig. 2. Vital staining with CM-DiI does not affect the morphology of iCell neurons. A) Nomarski images of iCell neurons stained with ﬂuorescent CM-DiI (5, 16 DIV). Scale
bar ¼ 20 mm, B) Drawings showing the typical morphology of iCell neurons stained with CM-DiI. C), D) Nomarski and ﬂuorescence images of intraneuronal particles (white ar-
rowheads) in cultured iCell neurons (12 DIV) stained with CM-DiI. For CM-DiI staining, neurons were incubated for 30 min in the presence of CM-DiI (1 mM), and incubated for
another 4 h in the absence of CM-DiI. Scale bar ¼ 20 mm. The magniﬁed image of the boxed area in (C) is shown in (D).
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may have been due to the different assay systems, rather than the
cytotoxic effect of CM-DiI. Using several markers, we previously
found that the majority of the moving particles labeled with CM-DiI
are composed of endosomes and lysosomes (1). The particles
monitored by DIC microscopy were composed of a macromolecular
complex and included lysosomes andmitochondria (1, 20). It is also
unlikely that CM-DiI has toxic effects on the transport. MTT assay
revealed no difference in cell viability between the cells treated
with vehicle control and those treated with CM-DiI (0.51 ± 0.21,
0.34 ± 0.11, n ¼ 6). In addition, vital staining of iCell neurons with
CM-DiI was done for only 30min. In summary, the CM-DiIestaining
procedure is unlikely to cause toxic effects under our experimental
conditions.
To enhance accuracy and reproducibility of monitoring intra-
neuronal transport, we ﬁrst selected iCell neurons with the longest
neurites (>70 mm in length) for multipoint estimation (Fig. 2C and D
and Materials and methods). The anterograde and retrograde
moving particles were observed crossing the virtual lines drawn
every 1 mm along the neurite for a 2-min period of time. The total
number of moving particles in iCell neurons was comparable to that
in chick DRG neurons (1). In addition, the amount of anterograde
transport was higher than the retrograde transport in iCell neurons
(Fig. 3A).
The instantaneous velocity histogram analysis revealed that a
large group of particles traveled slowly and another smaller group
traveled faster. Together, the groups accounted for the bimodal
pattern of the instantaneous velocity histogram for both antero-
grade and retrograde intraneuronal transport (Fig. 3B and C). Again,B
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Fig. 3. Intraneuronal transport of particles visualized with CM-DiI in the neurites o
(310.55 ± 3.49, 256.24 ± 3.68 particles, n ¼ 112). The histograms of anterograde (B) and
means ± SEM (n ¼ 11e19).no signiﬁcant differences were observed in the number of particles
in either velocity fraction for cells at 6 and 15 DIV (Fig. 3B and C).
We evaluated the velocity of anterograde and retrograde moving
particles (Figs. 3, 6 and 7). Some particles exhibited transport at a
higher velocity than previously reported (21, 22). To conﬁrm the
fast movement particles (Fig. 4A), we performed a kymograph
analysis on image data collected for a speciﬁc period of time to
show the spatiotemporal image of the particles (Fig. 4B). Each red
dotted line in Fig. 4B clearly shows the motion speed of particles,
with slopes representing speeds of 3.02, 3.48, 4.06, 4.52, and
4.99 mm/s, respectively.3.3. The effects of anti-neoplastic agents on intraneuronal transport
Because anti-neoplastic agents can cause distinct neurologic
side effects (12,23e26), we evaluated the effect of anti-neoplastic
agents on intraneuronal transport. The anti-neoplastic agents at
the concentration used in this study are effective in inhibiting the
axonal transport of chick DRG (1) and the growth of tumor cells (27,
28). Vincristine and paclitaxel decreased the total number of par-
ticles (Fig. 5), and the velocity histogram analysis revealed some
differences between their effects. The greatest effects of vincristine
on both anterograde and retrograde intraneuronal transport were
seen on the slow component, at a velocity around 1.2 mm/s. The
peak effects of paclitaxel on anterograde and retrograde intra-
neuronal transport occurred in the slow component, at a velocity
around 1.68 mm/s and 1.20 mm/s, respectively (Fig. 6). Oxaliplatin
reduced the number of particles that traveled at moderate to high
velocity (Fig. 6), without affecting the total number of particlesC
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Fig. 4. Kymograph analysis for proﬁling CM-DiIelabeled particles moving along the neurite of iCell neuron. A) The image of iCell neurons at 6 DIV. Each white dot represents a
CM-DiIelabeled particle. B) The spatio-temporal image (kymograph of vesicle movement) of particles in (A) is shown. Each red dotted line shows the motion speed of particles, with
slopes representing speeds of 3.02, 3.48, 4.06, 4.52, and 4.99 mm/s, respectively. The line with the largest slope represents a particle with fast movement.
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Fig. 5. Vincristine and paclitaxel reduce the total number of moving particles. The total number of moving particles labeled with CM-DiI in the neurites of iCell neurons. iCell
neurons were treated for 24 h with vehicle control, vincristine (0.1 nM), paclitaxel (1 mM), oxaliplatin (100 mM), cisplatin (100 mM), methotrexate (100 mM), or 5-ﬂuorouracil
(100 mM). Values are means ± SEM (n ¼ 9e26). *P < 0.05, **P < 0.01, ***P < 0.001.
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fects of these anti-neoplastic agents were unlikely to arise from a
secondary effect of their cytotoxicity in iCell neurons, because
propidium iodide staining revealed no difference in cell viability
between cell groups with and without treatment with anti-
neoplastic agents (data not shown). Cisplatin did not decrease
either the total number of particles (Fig. 5) or the number of par-
ticles that traveled at low to high velocity (Fig. 7).
5-FU and methotrexate are known to cause leukoencephalop-
athy (28). Neither had any notable effects on the total number of
particles (Fig. 5) or the number of particles that traveled at low to
high velocity in iCell neurons (Fig. 7).
4. Discussion
We demonstrate for the ﬁrst time the analysis of intraneuronal
transport in iPS neurons. Thus, combined with iPS technology, our
system could be a powerful tool for assessing intraneuronal
transport affected by neurotoxins and neurological disorders in
human neurons. We evaluated the acute effects of several anti-
neoplastic agents that have been previously shown to affect intra-
neuronal transport (1). Vincristine, paclitaxel and oxaliplatin sup-
pressed intraneuronal transport of iPS neurons. Cisplatin, however,
produced no effect on intraneuronal transport, which is in contrast
to our previous report indicating that it inhibits transport in chickDRG. This difference warrants neurotoxicity testing in human iPS
cells.
The majority of moving particles labeled with CM-DiI were
shown to be composed of endosomes and lysosomes (1). Because
mitochondria and lysosomes have estimated half-lives of 10 days
(29), a decrease in the transport may be mainly due to it being
disrupted in iCell neurons, rather than there being a decreased total
number of mitochondria and lysosomes. The half-life of early
endosomes is estimated to be 2min (30), and it is possible that anti-
neoplastic agents inhibit intraneuronal transport by affecting the
half-life of endosomes. Little is known, however, about possible
effects of antineoplastic agents on endosomal turnover rates.
Previous reports have suggested that the small vesicles con-
taining VAMP2 have rapid movement (about 0.3 mm/s) along mi-
crotubules (22). In our present study, we detected fast movement of
particles (Fig. 3). To conﬁrm it, we performed kymograph analysis
on image data collected for a speciﬁc period of time. This analysis
demonstrated the presence of moving particles with the speed of
3e5 mm/s (Fig. 4) and also suggested that our system can detect and
track fast-moving particles along neurites. The kinesin superfamily
proteins (KIFs) are known to be responsible for microtubule-
dependent intracellular transport, and each KIF has a character-
istic velocity, which varies from 0.2 to 1.5 mm/s. This velocity is
consistent with the speed of fast axonal transport detected in our
monitoring system.
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Fig. 6. Vincristine, paclitaxel, and oxaliplatin suppress a portion of the intraneuronal transport. Histograms of instantaneous velocity of intraneuronal transport 24 h after
treatment with vehicle control, vincristine (0.1 nM), paclitaxel (1 mM), or oxaliplatin (100 mM). Values are the means ± SEM (n ¼ 17e26). *P < 0.05, **P < 0.01, ***P < 0.001.
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transport (Figs. 5 and 7), in contrast to our previous report that it
inhibits transport in chick DRG neurons (1). The differing drug
sensitivity by cell type may be due to dissimilar cellular charac-
teristics of DRG and iCell neurons. For example, DRG neurons may
represent a well-differentiated chick peripheral neurons, while
iCell neurons appear to be un-polarized human central neurons
(Fig. 1). In both DRG neurons and iCell neurons, vincristine, pacli-
taxel, and oxaliplatin suppressed anterograde and retrograde
intraneuronal transport (1) (Fig. 6). In contrast to vincristine and
paclitaxel, however, oxaliplatin did not affect the total number of
particles (Fig. 5). The velocity histogram analysis demonstrated a
differential sensitivity for these agents of slow and fast components
of intraneuronal transport (Fig. 6). The analysis revealed that oxa-
liplatin suppressed the transport of particles moving at a certain
range of velocity (Fig. 6). The peak effects of oxaliplatin on anter-
ograde and retrograde intraneuronal transport occurred in the fast
component of a velocity. In contrast, the peak effects of vincristine
and paclitaxel on anterograde and retrograde intraneuronal
transport appeared in the slow component of a velocity (Fig. 6).
Although the detailed mechanisms are unknown, the differences
among these anti-neoplastic agents likely reﬂect their known andunknown sites of action. For example, vincristine inhibits the
polymerization of b-tubulin to a-tubulin, while paclitaxel stimu-
lates this action; both result in the appearance of microtubule
bundles and some aberrant structures in the mitotic phase of the
cell cycle (25). Meanwhile, suppression by oxaliplatin might be
linked to the rapid chelation of calcium by oxalate derived from the
drug. This chelation is associated with alteration of the voltage-
gated sodium channels through a pathway involving calcium ions
and can induce acute neuropathy (23, 24, 26).
Methotrexate and 5-FU have also been reported to have
neurological side effects. Methotrexate inhibits de novo purine
synthesis and induces astrocytosis in the brain (31). After it is
administered, 5-FU is converted to several active metabolites that
disrupt RNA synthesis and the action of thymidylase synthase,
which may cause neurotoxicity (32). However, these agents had
almost no effects on intraneuronal transport in either chick DRG or
iCell neurons. The side effects of methotrexate and 5-FU may be
induced by mechanisms other than disruption of intraneuronal
transport.
Defects in axonal transport have been implicated in the patho-
genesis of neurodegenerative disorders such as Alzheimer's disease
and Parkinson's disease, schizophrenia, and motor neuron diseases
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Fig. 7. Effects of cisplatin, methotrexate, and 5-ﬂuorouracil on intraneuronal transport. Histograms of instantaneous velocity of intraneuronal transport after treatment with
vehicle control, cisplatin (100 mM), methotrexate (100 mM), or 5-ﬂuorouracil (100 mM). Values are the means ± SEM (n ¼ 9e18). *P < 0.05, **P < 0.01.
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applicable for studying the molecular mechanisms of neurode-
generative disorders and for screening therapeutic agents.Author contributions
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